Clinical stage oncology startup Acrivon Therapeutics and Akoya Biosciences, a spatial biology company, have signed an agreement to co-develop, clinically validate, and commercialize Acrivon’s OncoSignature companion diagnostic (CDx) test.
The CDx test will be used to identify cancer patients that are suitable candidates for Acrivon’s targeted DNA damage response inhibitor treatment, ACR-268. Currently, Phase 2 clinical trials are being conducted on the drug candidate to treat patients with ovarian, endometrial, and urothelial cancers.
As part of the clinical development stage, the test will be run on Akoya's PhenoImager platform, which provides spatial phenotyping capabilities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.